FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	ROVAL
OMB Number:	3235-028
Estimated average	burden
hours por rosponso	0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person * Schorno Dean L (Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD. (Street) SOUTH SAN FRANCISCO, CA 94080			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL] 3. Date of Earliest Transaction (Month/Day/Year) 01/23/2019						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below) EVP & Chief Financial Officer 6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person							
			4. If Amendment, Date Original Filed(Month/Day/Year)													
(City) (State) (Zip)			Table I - Non-Derivative Securities Acc						es Acqu	uired, Disposed of, or Beneficially Owned						
(Instr. 3) Date		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, if any (Month/Day/Year		oate, if C	(Instr. 8)		4. Securities Acquir (A) or Disposed of ((Instr. 3, 4 and 5)					,	Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
							Code		mount (A) or	Price	or Indirect (I)			(IIISII. 4)		
			Table II					ired, Dispo	ntly valid OMI sed of, or Bend evertible secur	eficially (Dei.				
Derivative	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transact	tion S		er of e (A) ed of	ired, Dispo	sed of, or Bend evertible secur ercisable and Date	7. Title of Unc	Owned e and Anderlying	mount	8. Price of Derivative Security (Instr. 5)		Owners Form o	Ownersh y: (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transact	ttion I	5. Number Derivative Securities Acquired or Dispos (D)	er of e (A) ed of	ired, Dispo options, co 6. Date Ex Expiration	sed of, or Bend evertible securerisable and Date y/Year)	7. Title of Unc	e and Anderlying ties 3 and 4)	mount)	Derivative Security	Derivative Securities Beneficially Owned Following	Owners Form of Derivat Securit Direct or India	ship of Indire Benefici Ownersh (Instr. 4)
1. Title of Derivative Security (Instr. 3) Employee Stock Option (right to buy)	Conversion or Exercise Price of Derivative Security	Date	3A. Deemed Execution Date, if any	(e.g., pu 4. Transact Code (Instr. 8	ttion I	5. Number Derivative Securities Acquired or Dispos (D) (Instr. 3, 4 and 5)	er of e (A) ed of 4,	ired, Dispo options, con 6. Date Ex- Expiration (Month/Da	sed of, or Bend evertible securerisable and Date y/Year)	7. Title	Owned e and Anderlying titles 3 and 4) Arrow of	mount)mount r fumber	Derivative Security	Derivative Securities Beneficially Owned Following Reported Transaction	Owners Form of Derival Securit Direct or India (s) (I) (Instr. 4	ship of Indire Benefici Ownersh (Instr. 4)

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Schorno Dean L RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			EVP &Chief Financial Officer			

Signatures

/s/Dolly Vance (Attorney-in-Fact)	01/25/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.